our vision
MWH was founded on the vision of NAD+ therapeutics becoming ubiquitous across the fields of medicine, wellness, anti-aging, and cosmetics. Our founders and scientific advisory board include the original pioneers of NAD+ therapeutics in the United States, physicians, scientists and pharmacologists.
founders
Richard F. Mestayer, III, MD
Co-Founder
Co-Chairman of the Board
President
Chairman of the Scientific Advisory Board
Richard is the leading authority in the USA on IV NAD+ infusion. As medical director at Springfield Wellness Center, he developed standard-setting protocols in IV NAD+ for addiction cravings and withdrawal and neurodegenerative disorders such as ALD and PD. As medical director at NAD Research, Inc., he coordinates an international group of researchers working towards greater understanding of NAD+. As founder of BR+MD Consultants he trains healthcare providers nationwide in effective IV NAD+ treatment. He has presented at the Soc for Neuroscience, J of Gerontology and Geriatric Research, Frontiers in Aging: Neuroscience, Case Reports and Literature Review, and at the BR+NAD Brain Restoration Summits. For 27 years, he directed the behavioral medicine and stress treatment units at Ochsner Foundation Hospital and taught courses in psychosomatic medicine and personality disorders for Ochsner’s Psychiatric Residency program. Richard earned his MD at Louisiana State University Medical Center in 1974 and completed an internship in medicine at Alton Ochsner Medical Foundation, New Orleans, LA, in 1975, where he was named medical “Intern of the Year.” He completed his residency in psychiatry at the University of Virginia Department of Psychiatry in Charlottesville in 1978 and is board certified in psychiatry and neurology. Richard was co-Chief Resident of Psychiatry at University of Virginia Medical School.
Dr. Fenton Le Bon, MD, MBA
Co-Founder
Co-Chairman of the Board
CEO
Fenton is Molecular World Health's co-founder, co-chairman and CEO. He oversees and directs all divisions and day to day operations, and with Dr. Richard Mestayer III, is responsible for all product development, decisions and guiding vision of the company. Prior to co-founding Molecular World Health, Fenton spent his career in traditional psychiatric practice and alternate medical practice building and development in the private and public sector in the Southeastern US and Argentina.
In Georgia he founded Eastman Mental Health, an integrated outpatient practice and programs such as State based inpatient, long stay Wilderness Programs for the treatment of Substance Use. Previous to this, Fenton founded a private psychiatric practice and corporate consulting firm in Miami, Florida focused on developing new treatment modalities for Eating Disorders and Addictions.
Fenton earned his MD from The Medical College of Pennsylvania and completed his internship and Residency in Psychiatry at The University of Florida School of Medicine. He received his MBA from the Warrington School of Business at The University of Florida.
Paula N. Mestayer, M.Ed., LPC, FAPA
Co-Founder
Secretary
Corporate Board Member
Paula is a psychotherapist and pioneered the development of protocols in the USA for utilizing NAD+ to effectively treat addiction with minimal withdrawal symptoms and without substituting another narcotic. She is the founder of Springfield Wellness Center and has helped thousands of people successfully break the cycle of rehab/relapse. She is a presenter at NAD and addiction conferences across the USA, serves on the board of NAD Research, Inc., and is the author of Addiction: Dark Night of the Soul; NAD+: The Light of Hope. She is a Licensed Professional Counselor (LPC), a Fellow of the American Psychotherapy Association (FAPA), and a member of the American Counseling Association and the Louisiana Counseling Association.
Paula earned her M.Ed in education and did independent study in psychotherapy from Tulane University and completed her clinical internship at the Manhattan Children’s Psychiatric Hospital.
scientific advisory board
Ross Grant, PhD
Dr. Ross Grant is considered to be one of the world’s foremost scientific experts in NAD+. He is a clinical biochemist / biochemical pharmacologist and CEO of the Australasian Research Institute at Sydney Adventist Hospital in Australia.
​
Dr. Grant has contributed to over 100 academic publications in his research area which focuses on understanding how a person’s lifestyle factors changes their body’s biochemistry and immune activity, driving it toward either health or disease.
​
Dr. Grant has worked on the influence of the constellation of lifestyle factors on natural killer (NK) cell activity, redox balance (i.e. oxidative stress) and NAD+ metabolism and how these influence cellular degeneration, particularly in the brain and central nervous system.
Mark S. Gold, MD
Dr. Gold, a 1975 graduate of the University of Florida College of Medicine, is an author, inventor, and mentor who has had over one thousand peer-reviewed publications, thirty thousand academic research citations, and an H index of 90 all since the beginning of his academic career at the University of Florida College of Medicine and Yale University School of Medicine in the 1970s. Dr. Gold has made impactful contributions to psychiatry, neuroendocrinology, radiation oncology, transplant, biology, orthopedic surgery, public health, pain, obesity medicine, and substance use disorders. He is best known for developing the pioneering translational laboratory to human research methods of discovery for addiction and psychiatry.
Dr. Gold was recognized with the Faculty Research Prize at his UFCOM Graduation in 1975 (with honors). He completed his internship, residency, and held his first Faculty appointment at YSM. His first position at UFCOM was as a Professor of Neuroscience in 1990, and he started his lab and work on new treatment development using animal models of tobacco addictions and secondhand smoke. A man of many hats; Founding Member of the McKnight Brain Institute, Founder of the Division of Addiction Medicine at UFCOM, Professor, Eminent Scholar, Distinguished Professor, UF’s 17th Distinguished Alumni Professor, and Emeritus Eminent Scholar all during his 25 years at UF. Dr. Gold is currently working as a part-time academic and as an Affiliate Partner in private equity at Lindsay Goldberg in NYC.
David Lefer, PhD
Dr. Lefer is the director of LSU Health New Orleans’ Cardiovascular Center of Excellence.
​
As a professor of pharmacology, he has been working in the fields of myocardial protection and coronary physiology for more than 20 years.
​
Dr. Lefer is an internationally recognized leader in understanding the role of nitric oxide and other nitrogen oxide-metabolites in ischemia-reperfusion injury to the heart. His laboratory was among the first to demonstrate the profound loss of endothelial cell-derived nitric oxide from the coronary circulation following coronary artery occlusion and reperfusion.
Dr. Lefer’s laboratory was the first to report on the potent cardioprotective actions of nitric oxide in acute myocardial infarction and congestive heart failure.
Robert W. Benson, MD
Dr. Benson is a board-certified dermatologist and cosmetic surgeon who has been a leader and innovator in clinical practice for over forty years in both the US and overseas. He brings to bear an entrepreneurial perspective combined with experience in practical, tangible results-driven medical and surgical modalities. Beginning in 1980 as a solo practitioner, he built the third largest dermatology practice in the southern US, during which time he was among the first physicians to perform such innovative procedures as liposuction, laser liposuction, laser resurfacing, fat transfer, and a host of other techniques both in Louisiana and in New Zealand, where he lived for five years inthismelanoma capital of the world. His broad interests in nutraceuticals and cosmeceuticals led to one of the first true medical spas in the South, concentrating on scientifically proven products and modalities, both conventional and alternative, which promote skin health and rejuvenation.
Dr. Benson earned his MD at LSU Medical Center in 1976, followed by internship and residency at Charity Hospital of Louisiana. He was Chief Resident of the combined LSU-Tulane dermatology residency program in 1979-80. Since that time, he has been medical director of Benson Dermatology and QnA Medical Spa in the US and Cosmedex Dermatology and Cosmetic Surgery in New Zealand. Dr. Benson has been a member of numerous national and state medical societies and designated a Fellow of the American Academy of Dermatology, the American Society of Cosmetic Surgery, the American Society of Dermatologic Surgery, and the International Society of Dermatology.
Fernando Secin, MD, PhD
As a Memorial Sloan Kettering trained practicing urological surgeon and researcher, Dr. Secin will bring his expertise towards advising Molecular World Health on new therapeutics for NAD and similar molecules in the field of surgical wound and pain care, as well as other new surgical and oncological initiatives.
A native of Argentina, Dr. Secin received his medical degree from the University of Buenos Aires School of Medicine and completed his General Surgery Residency and Urology Residency at CEMIC University Hospital, Buenos Aires, and his Doctoral Thesis at the University of Buenos Aires School of Medicine. He completed his clinical and research Fellowship on Urologic Oncology at The Memorial Sloan Kettering Cancer Center, NYC, with special training in minimally invasive surgery. Dr. Secin is a former Associate Professor of Urology at CEMIC University Hospital and at the Urology Department of the University of Buenos Aires School of Medicine.
Dr. Secin is a current associate staff surgeon of Urology at the primary Cleveland Clinic in Ohio. He has authored multiple publications and is a frequent lecturer at international meetings and live surgical demonstrations in Latin American countries.
Susan Broom Gibson, PhD
Dr. Broom Gibson is an Associate Professor of Psychology at William Carey University in Hattiesburg, MS and a research consultant for Springfield Wellness Center in Springfield, LA. She received her PhD in Experimental Psychology from the University of Mississippi in 2002. At UM, she conducted substantial animal research with the Department of Psychology and the National Center for Natural Products Research. She studied the therapeutic potential and abuse liability of both pharmaceutical and natural products for chronic inflammatory pain and anxiety. She also conducted experiments investigating the neurotoxic and behavioral effects of chronic methamphetamine exposure in rats. She completed research fellowships at Boston University School of Medicine (2002-2004) and Tulane University School of Medicine (2004-2006). Since 2008, she has worked as lead researcher for Springfield Wellness Center and co-chair of NRI’s Scientific Advisory Board, investigating the therapeutic potential of NAD+ for clinical applications, including Substance Use Disorders, Mood and Anxiety Disorders, Migraine Headache, Parkinson’s and Alzheimer’s Disease.
Ray Wilkes, RPh
Mr Wilkes has just completed 50 years as a pharmacist. The last 10 years were as the Compounding Pharmacist-In-Charge at Archway Apothecary of Covington Louisiana.
Mr Wilkes has undertaken USP <795> and USP <797> compounding training from PCCA in Houston, Critical Point in New Jersey, American Compounding Academy in Memphis and from McWhorter School of Pharmacy in Birmingham, after graduating from NLU School of Pharmacy in 1972.
Mr Wilkes has successfully improved on seven different compounding PCCA formulas that Archway uses and has formulated 'Face Paste' with NAD+, and NAD+ subcutaneous injections.